Innovation in the Pharmaceutical Industry¶
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics, 47, 20-33.
Cited by¶
2 citations across 2 artifacts.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Stage Gate Process
- A single worked instance shows the substance: an oncology drug advancing through microdosing, single-arm safety, mid-stage efficacy, and large-scale efficacy gates, each producing evidence that licenses the next-stage commitment, each with explicit go and kill criteria, the total commitment sliced rather than committed up front, and roughly one in ten Phase-I candidates reaching approval — by design, not by failure.
This sourceDocuments the cost-staging and roughly one-in-ten Phase-I-to-approval attrition of oncology and other drug development.
- A single worked instance shows the substance: an oncology drug advancing through microdosing, single-arm safety, mid-stage efficacy, and large-scale efficacy gates, each producing evidence that licenses the next-stage commitment, each with explicit go and kill criteria, the total commitment sliced rather than committed up front, and roughly one in ten Phase-I candidates reaching approval — by design, not by failure.
- Time
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Not recorded. Neither this nor any other of the 2 citations of this work carries a recorded support check.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:1337408b0264 · see in the full table